![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Callisto Pharmaceuticals Announces $3.02 Million Private Placement
Callisto Pharmaceuticals Announces $3.02 Million Private Placement
March 10, 2005
Callisto Pharmaceuticals, a biopharmaceutical company focused on the development of drugs to treat cancer and osteolytic bone disease, announced the completion of a private placement of approximately 1.99 million shares of its common stock at a per share price of $1.52, for aggregate gross proceeds of approximately $3.02 million. The financing was led by current institutional shareholders and included certain members of the company's management.
Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=82434)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct